The purpose of this contract is to evaluate and modulate the molecular pathways involved in regulating and enhancing HIV envelope/antigen expression in mammalian cell lines and to accelerate…
Ended Definitive Contract Awarded Last action
- Contract number
- 75N93018C00017
- Awardee
-
Antagen Biosciences Inc. UEI HXD6EFH2ND57
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $599,997
Award facts
- Opportunity
-
- SBIRPHS20181 Solicitation number
- Contract value 100% obligated
- $599,997.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- Set-aside
- Total Small Business
- Competition
- Full and Open Competition after exclusion of sources · 4 offers Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Roxbury, MA 02118, USA
- Research
- SBIR Program Phase I Action
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Original award | $599,997 |
About this award
This federal contract was awarded by the Department of Health and Human Services, National Institutes of Health, National Institute of Allergy and Infectious Diseases (NIAID) to Antagen Biosciences Inc., doing business as Antagen Pharmaceuticals. The $599,997.00 contract is a Firm Fixed Price Definitive Contract under the SBIR Program Phase I Action for the Major Program Code DAIDS. The purpose of the contract is to evaluate and modulate the molecular pathways involved in regulating and enhancing HIV envelope/antigen expression in mammalian cell lines, and to accelerate development of purification platforms in a CGMP manufacturing setting. This contract is set aside for total small business participation.
Description
The purpose of this contract is to evaluate and modulate the molecular pathways involved in regulating and enhancing HIV envelope/antigen expression in mammalian cell lines and to accelerate development of purification platforms in a cgmp manufacturing setting.
Quick answers
Who was awarded contract 75N93018C00017?
75N93018C00017 was awarded to Antagen Biosciences Inc. by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on July 26, 2018.
How much is contract 75N93018C00017 worth?
The government has obligated $599,997 on 75N93018C00017.
Was contract 75N93018C00017 competed?
The extent of competition for 75N93018C00017 was full and open competition after exclusion of sources. The government received 4 offers. It was set aside: Total Small Business.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award